Aurinia and CCO Max Colao mutually agree to separation effective July 22

Aurinia Pharmaceuticals Inc.

Max Colao, Chief Commercial Officer, will cease employment on July 22, 2022 by mutual agreement.
Severance includes 12 months base salary ($488,835) plus eligibility for performance bonus (target $244,418).
COBRA benefits for up to 12 months if elected.
No replacement named; separation agreement expected to mirror existing employment terms.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Max Colao

Chief Commercial Officer

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2022-07-22
Filed: July 15, 2022, 7:59 PM ET

On July 11, 2022, Aurinia Pharmaceuticals Inc. and Max Colao, our Chief Commercial Officer, mutually agreed that Mr. Colao would cease his employment with Aurinia, effective July 22, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Max Colao departed as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..

Action: mutually agreed to cease employment
Role: Chief Commercial Officer

Exact text from the filing

On July 11, 2022, Aurinia Pharmaceuticals Inc. and Max Colao, our Chief Commercial Officer, mutually agreed that Mr. Colao would cease his employment with Aurinia, effective July 22, 2022.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-018937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.